PREVENT Phase 3 trial

Clinical Efficacy of Soliris Supported by Pharmacological Analysis

An analysis of pharmacological data supports the observed clinical efficacy of Soliris (eculizumab) in significantly reducing relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) given the therapy in the PREVENT Phase 3 clinical trial. At its approved dose, Soliris led to rapid, sustained, and complete suppression…

#AANAM – Soliris Has Long-term Relapse Prevention

Soliris (eculizumab) significantly reduced the risk of disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD) over nearly three years, according to new data from the clinical trial PREVENT and its extension study. Additional findings project that long-term Soliris treatment may reduce relapse risk over the course of…

#MDA2021 – Soliris Did Not Increase Infection Risk in NMOSD, Trials Show

Treatment with Soliris (eculizumab) does not increase the risk of infections or serious infections among people with neuromyelitis optica spectrum disorder (NMOSD) and antibodies against the protein aquaporin-4 (AQP4), even in those receiving accompanying immunosuppressive therapies. Those were the findings from a post hoc analysis of…

Relapses Can Obscure Quality-of-life Ratings in Trials

Experiencing disease relapses after receiving a placebo in a clinical trial may change the perception of health in participants with neuromyelitis optica spectrum disorder (NMOSD) and lead to an underestimation of the disease’s impact on quality of life, a study shows. This effect — known as “response shift” —…